MEG3 Human shRNA Plasmid Kit (Locus ID 55384)
CAT#: TL320132
MEG3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 5,740.00
货期*
现货
规格
Cited in 4 publications. |
经常一起买 (3)
Specifications
Product Data | |
Product Name | MEG3 Human shRNA Plasmid Kit (Locus ID 55384) |
Locus ID | 55384 |
Synonyms | FP504; GTL2; LINC00023; NCRNA00023; onco-lncRNA-83; prebp1; PRO0518; PRO2160 |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | MEG3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 55384). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NR_002766, NR_003530, NR_003531, NR_033358, NR_033359, NR_033360, NR_046464, NR_046465, NR_046466, NR_046467, NR_046468, NR_046469, NR_046470, NR_046471, NR_046472, NR_046473, BC023543, BC036882, BC051294, BC062783, BC092509 |
Summary | This gene is a maternally expressed imprinted gene. Multiple alternatively spliced transcript variants have been transcribed from this gene and all of them are long non-coding RNAs (lncRNAs). This gene is expressed in many normal tissues, but its expression is lost in multiple cancer cell lines of various tissue origins. It inhibits tumor cell proliferation in vitro. It also interacts with the tumor suppressor p53, and regulates p53 target gene expression. Its deletion enhances angiogenesis in vivo. Many experimental evidences demonstrate that this gene is a lncRNA tumor suppressor. [provided by RefSeq, Mar 2012] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (4)
The use of this RNAi has been cited in the following citations: |
---|
Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3
,null,
Neuro-Oncology
,PubMed ID 32459347
[MEG3]
|
Long Noncoding RNA (lncRNA) Maternally Expressed Gene 3 (MEG3) Participates in Chronic Obstructive Pulmonary Disease through Regulating Human Pulmonary Microvascular Endothelial Cell Apoptosis
,Bi, H;Wang, G;Li, Z;Zhou, L;Zhang, M;Ye, J;Wang, Z;,
Med Sci Monit
,PubMed ID 32201430
[MEG3]
|
Mechanism associated with aberrant lncRNA MEG3 expression in gestational diabetes mellitus
,Zhang, H;,
Exp Ther Med
,PubMed ID 31656536
[MEG3]
|
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163
,Su, L;Han, D;Wu, J;Huo, X;,
Tumour Biol.
,PubMed ID 26482610
[MEG3]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...